ts. Passive immunoprophylaxis with immune globulins may be indicated for immunocompromised persons instead of, or in addition to, vaccination. When exposed to a vaccine-preventable disease such as measles, severely immunocompromised children should be considered susceptible regardless of their vaccination history.
ADVERSE REACTIONS
Severe
neutropenia / Delayed / 63.0-79.0
thrombocytopenia / Delayed / 59.0-59.0
anemia / Delayed / 34.0-55.0
leukopenia / Delayed / 21.0-21.0
fatigue / Early / 12.0-12.0
pleural effusion / Delayed / 10.0-10.0
hyperbilirubinemia / Delayed / 9.0-9.0
headache / Early / 1.0-6.0
peripheral neuropathy / Delayed / 0-6.0
seizures / Delayed / 1.0-6.0
hypoalbuminemia / Delayed / 6.0-6.0
hypokalemia / Delayed / 6.0-6.0
dyspnea / Early / 6.0-6.0
weakness / Early / 5.0-5.0
fever / Early / 5.0-5.0
hypoesthesia / Delayed / 2.0-4.0
dehydration / Delayed / 4.0-4.0
elevated hepatic enzymes / Delayed / 2.0-4.0
hypoglycemia / Early / 4.0-4.0
infection / Delayed / 3.0-3.0
drowsiness / Early / 0-2.0
ataxia / Delayed / 1.0-2.0
hypomagnesemia / Delayed / 2.0-2.0
hypocalcemia / Delayed / 2.0-2.0
hypotension / Rapid / 2.0-2.0
confusion / Early / 2.0-2.0
petechiae / Delayed / 2.0-2.0
leukoencephalopathy / Delayed / 1.0-1.0
coma / Early / 1.0-1.0
muscle paralysis / Delayed / 1.0-1.0
intracranial bleeding / Delayed / 1.0-1.0
Guillain-Barre syndrome / Delayed / 0-1.0
hydrocephalus / Delayed / 1.0-1.0
paresthesias / Delayed / 0-1.0
diarrhea / Early / 1.0-1.0
stomatitis / Delayed / 1.0-1.0
constipation / Delayed / 1.0-1.0
abdominal pain / Early / 1.0-1.0
vomiting / Early / 0-1.0
hyperglycemia / Delayed / 1.0-1.0
sinus tachycardia / Rapid / 1.0-1.0
pneumothorax / Early / 0-1.0
sinusitis / Delayed / 1.0-1.0
myalgia / Early / 1.0-1.0
arthralgia / Delayed / 1.0-1.0
rhabdomyolysis / Delayed / 0-1.0
depression / Delayed / 1.0-1.0
asthenia / Delayed / 1.0-1.0
tumor lysis syndrome (TLS) / Delayed / Incidence not known
Moderate
peripheral edema / Delayed / 15.0-15.0
edema / Delayed / 11.0-11.0
chest pain (unspecified) / Early / 5.0-5.0
wheezing / Rapid / 5.0-5.0
blurred vision / Early / 4.0-4.0
amnesia / Delayed / 3.0-3.0
nystagmus / Delayed / 1.0-1.0
paresis / Delayed / 1.0-1.0
hypertonia / Delayed / 1.0-1.0
encephalopathy / Delayed / 1.0-1.0
aphasia / Delayed / 1.0-1.0
neuropathic pain / Delayed / 1.0-1.0
dysarthria / Delayed / 1.0-1.0
hyperuricemia / Delayed / Incidence not known
Mild
nausea / Early / 41.0-41.0
cough / Delayed / 25.0-25.0
dizziness / Early / 21.0-21.0
anorexia / Delayed / 9.0-9.0
epistaxis / Delayed / 8.0-8.0
back pain / Delayed / 8.0-8.0
chills / Rapid / 8.0-8.0
insomnia / Early / 7.0-7.0
tremor / Early / 4.0-5.0
dysgeusia / Early / 3.0-3.0
lethargy / Early / 1.0-1.0
hyporeflexia / Delayed / 1.0-1.0
DRUG INTERACTIONS
Abciximab: Due to the thrombocytopenic effects of nelarabine, an additive risk of bleeding may be seen in patients receiving concomitant platelet inhibitors.
Anagrelide: Due to the thrombocytopenic effects of nelarabine, an additive risk of bleeding may be seen in patients receiving concomitant platelet inhibitors.
Anticoagulants: Due to the thrombocytopenic effects of nelarabine, an additive risk of bleeding may be seen in patients receiving concomitant anticoagulants.
Aspirin, ASA; Dipyridamole: Due to the thrombocytopenic effects of nelarabine, an additive risk of bleedi |
